Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation
暂无分享,去创建一个
F. Jardin | P. Gaulard | H. Tilly | F. Lemonnier | N. Mounier | C. Haioun | E. Itti | S. Becker | J. Dupuis | L. Roulin | K. Belhadj | H. Vellemans | F. Le Bras | V. Camus | L. Veresezan | T. El Gnaoui | E. Poullot | C. Cazelles | M. Carvalho | Clarisse Cazelles | Muriel Carvalho
[1] Matthew J. Frigault,et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Byth,et al. Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation , 2020, Leukemia & lymphoma.
[3] F. Cabanillas,et al. A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). , 2019, Clinical lymphoma, myeloma & leukemia.
[4] L. Sehn,et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Salles,et al. Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review , 2019, Leukemia & lymphoma.
[6] I. Flinn,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.
[7] R. Houot,et al. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study , 2018, Leukemia.
[8] Jian-yong Li,et al. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. , 2018, The Lancet. Haematology.
[9] R. Marcus,et al. Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study , 2017, Leukemia and Lymphoma.
[10] J. Cerhan,et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.
[11] P. Gaulard,et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial , 2013, Haematologica.
[12] Michael L. Wang,et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial , 2013, Leukemia.
[13] R. Gressin,et al. High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B‐cell lymphoma in first relapse: results of the R‐NIMP GOELAMS study , 2013, British journal of haematology.
[14] M Ladetto,et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[16] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Copie-Bergman,et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[20] W. Hryniuk,et al. The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Cerhan,et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.
[22] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[23] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.